When on 13 April 2025 the distribution activities of CEF (Cooperativa Esercenti Farmacia) were operationally transferred to the newco QFarma S.r.l., and subsequently UNICO La Farmacia dei Farmacisti merged by incorporation into QFarma, Italian pharmaceutical intermediate distribution lived its most significant transformation of the last two decades. €2.5 billion aggregated revenue, 12,000 pharmacies served, 2,000 employees, 20 operational branches, over 3,800 pharmacist members (of which 1,200 affiliated to the network): the first major cooperative group of Italian pharmaceutical distribution was born, controlled 51% by CEF and 49% by the five cooperatives that formed UNICO (Unione farmaceutica novarese, Codifarma, Unione farmacisti del Friuli Venezia Giulia, Cosifar and others).
A note for non-Italian readers: QFarma is a uniquely Italian operation that consolidates two historic cooperative entities of Italian pharmaceutical wholesale, both controlled by pharmacist members. The cooperative model is distinct from the capital-owned chain model (which I cover in a separate article on Italian pharmacy chains) and has different governance, ownership and strategic dynamics.
AGCM (Italian competition authority) authorisation came on 21 July 2025, clarifying the competition conditions the newco had to respect. Vittorino Losio, QFarma President, defined the operation at presentation: “Q Farma is born as a concrete and structured response to sector transformations — a project strongly wanted by pharmacists for pharmacists”. The three declared strategic pillars: efficiency and sustainability, value proposition enhancement, strong identity to represent and defend the independent pharmacy’s professional autonomy.
Fourteen months after QFarma’s operativity, it’s time for a first assessment. What has concretely changed in the Italian intermediate distribution market? What operational effects have been seen on pharmacist clients? And — question weighing most on 2026-2027 strategic choices — what is the competitive picture for regional independent intermediate distributors who remain outside the cooperative pole and the two-three large-size private players?
The pre-merger picture: Italian intermediate distribution at 2024
To grasp the change’s scope, it’s worth recalling the pre-merger picture. As of 2024 — the last complete year before the QFarma operation — the Italian DIF panorama was articulated as follows:
National private players: Comifar (over €4 billion revenue, historical sector leader), Alliance Healthcare (Walgreens Boots Alliance group, widespread presence), DPC Group, some smaller realities with national coverage.
Historical pharmacist cooperatives: CEF (Cooperativa Esercenti Farmacia, Lombardy and Emilia-Romagna based), UNICO (federation of northern regional cooperatives), So.Farma.Morra (Southern Italy, Campania first), Sofarma (some areas), and other territorial cooperative realities.
Private regional independent wholesalers: about sixty operators of various sizes serving mainly their own region or macro-area, with revenue typically in the €10-50 million range. It’s in this category that the typical Optivo DIF client base concentrates (such as Univex), together with the specialised carriers that serve it (such as Logital).
Specialised distributors: some operators focused on niches (specialty, premium cold chain, advanced ATMP therapies, veterinary).
The overall picture: approximately 60 total wholesalers, halved in the last 20 years by progressive consolidation. A sector under structural pressure for the reasons discussed in the DIF EBITDA analysis: margin regulated by law, DD/DPC at 30% of market vs 5% EU, pharmacy chain erosion, working capital squeezed.
The CEF-UNICO merger inserted itself exactly at this pressure point, consolidating two significant cooperative realities into a single pole that — by size — becomes direct competitor to Comifar and the other large private players.
The first 14 months: what was seen operationally
It’s not easy, 14 months after operativity, to separate “QFarma” effects from external factors (2025 Italian Budget Law, TAR ruling of 9 February 2026 on generics, chain CeDi pressure). Some lines have however clarified.
Rationalisation of overlapping branches. CEF and UNICO had some geographic overlaps, particularly in some North-West and Centre areas. The newco initiated a rationalisation plan that led — according to sector information — to the operational reduction of some branches with activity absorption into others. The total number of branches (20 declared at launch) remained almost stable, but the geographic map redrew.
IT and operational integration. The integration of management systems, planning processes and operational procedures between CEF and UNICO is a complex activity that, on similar operations’ benchmarks, typically requires 18-30 months to complete. At 14 months, integration is still ongoing and in some areas (product master data, TMS integration, commercial conditions alignment) residual aspects are still being managed. The official narrative is of “zero redundancies, internal reconversion”.
Pressure on purchase prices. A newco of €2.5 billion revenue has significant negotiating leverage with pharmaceutical manufacturers. The first signals — not officially confirmable — indicate that QFarma revised purchase conditions with main manufacturers, obtaining improved terms reflected in greater competitiveness toward network-adhering pharmacies and new commercial proposals to pharmacists evaluating aggregation.
Communication toward independent pharmacies. QFarma launched structured communication campaigns toward Italian pharmacists — focused on professional autonomy, on the cooperative model, on “pharmacists for pharmacists” — which led to a significant rate of new adhesions. Numerical details are not public but the pattern is visible on the ground.
The effect on the competitive market
At 14 months, market restructuring is clear on three dimensions.
Comifar remains leader, but the gap shrinks
Comifar — the historical Italian market leader with over €4 billion revenue — remains number one by size, but the gap with QFarma has significantly narrowed. From a structure of “1 leader + a pile of smaller players”, the market is moving toward “1 private leader + 1 cooperative leader + several significant national players + numerous regional players”. It’s a more balanced and tendentially more competitive structure, but also more demanding for those without scale.
Regional independent distributors left alone feel the pressure
For regional independent wholesalers — the segment most relevant for Optivo as client base — the new cooperative pole’s pressure is significant. Operational effects seen in the first 14 months:
- Marginal erosion of pharmacies deciding to adhere to QFarma. Typically 2-5% of portfolio pharmacies for a medium regional distributor, concentrated in areas where QFarma has direct presence.
- Pressure on commercial conditions. Pharmacies staying with the regional independent can use QFarma as negotiation benchmark, requesting more favourable conditions (service levels, discounts, returns management).
- Purchase difficulty. On some product lines, regional independents see delivery times from manufacturers lengthen or economic conditions worsen, because manufacturers favour large players in quantity allocation.
The net effect: regional independents tend to accelerate their strategic choice — sell to a larger pole, federate with other independents, specialise on niches. Status quo is no longer sustainable for those already marginally at the limit.
The dialogue for a second cooperative pole (in formation?)
A phenomenon that has lit up in months following QFarma’s birth — not yet consolidated, to follow — is the dialogue among cooperatives remaining outside the CEF-UNICO pole. So.Farma.Morra (rooted in Southern Italy), Sofarma (some areas), and other regional cooperative realities are evaluating forms of aggregation that could lead to the birth of a second Italian cooperative pole, perhaps smaller than QFarma but sufficient to recover part of the lost negotiating leverage.
Timing is uncertain: cooperative aggregations require statutory paths, pharmacist member consultation, AGCM approvals, operational integrations. On benchmarks, an operation of this kind requires 18-36 months between announcement and operativity. If realised, the Italian competitive picture in 2027-2028 will be further different.
The regional independent’s dilemma: three exit paths
For a regional independent DIF wholesaler — typically €15-40 million revenue, 100-300 served pharmacies, one or two region coverage, EBITDA structurally compressed — coexistence with QFarma and market consolidation leads to a concrete strategic question. Three practicable exit paths.
Path 1 — Sell to a larger pole
The most radical option. Total or majority sale to the cooperative pole (QFarma or potential future second pole) or to a private player (Comifar, Alliance Healthcare, others). Advantages: liquidity for members, access to a scaled cost structure, elimination of daily operational pressures. Disadvantages: loss of autonomy, territorial identity, in many cases also of historical roots with local pharmacists. It’s a typically generational choice (transition between first-generation owners and children).
Path 2 — Federate with other independents
The least traumatic option. Purchase federation among regional independent distributors that remain operationally autonomous but share negotiating leverage with manufacturers and access to common technological platforms. Works if there are geographic affinities (contiguous regions) and cultural affinities (compatible operating models), and if the overall critical mass is sufficient to be relevant with manufacturers (€100-200 million aggregated revenue as typical threshold).
Path 3 — Specialise on niches
The positioning option. Shift the distributor’s mix toward segments where margin is not regulated (veterinary, parapharmacy, dermocosmetics, supplements), where chains are less present (rural areas, small towns), or where technical specialisation creates entry barriers (specialty premium cold chain, ATMP, advanced GDP audit). It’s the most “innovative” survival path but also the most demanding: it requires investments, commercial redesign, staff training, sometimes new regulatory certifications.
None of the three paths is “obvious”. Choices are dictated by specific context, but the relevant fact is that the non-choice — staying as one is — is no longer a path. Market consolidation is ongoing, and coexistence between a large structured cooperative pole and a regional wholesaler operating with 1990s systems and processes has limited time.
The effect on an often-undervalued variable: operational planning
There is an effect of post-QFarma dynamics that we see concretely on Optivo’s DIF clients, and that deserves to be called out. On regional independents, competitive pressure has accelerated the adoption of strategic planning tools — scenario simulation, pharmacy-by-pharmacy cost-to-serve, progressive fixed-route recomposition, dynamic intraday replanning. The pattern is clear.
The reason is economic. On a sector average EBITDA of 1.5%, and with erosive margin accentuated by consolidation, the regional distributor can no longer afford to operate “by feel”. The 0.2-0.5 EBITDA points recoverable through cost-to-serve discipline and route optimisation are often the difference between staying and yielding. In the first commercial calls with regional wholesalers in 2025-2026 we see this theme explicitly raised: it’s no longer a choice of incremental efficiency, it’s a survival choice.
For QFarma and other large players, planning tools are by now standard. For regional independents, they are the tool that makes the service difference competitive: the regional maintaining 2-3 hour order-to-delivery averages (vs 12-hour regulatory baseline), managing intraday urgencies, having an updated cost-to-serve map on its pharmacies, has a solid commercial argument toward independent pharmacies of its territory.
Frequently asked questions
Is QFarma a single company or a consortium of cooperatives?
QFarma is a capital company (S.r.l.) controlled 51% by CEF (Cooperativa Esercenti Farmacia) and 49% by the five cooperatives that formed UNICO. The identity is therefore cooperative (control by pharmacist members) but the legal form is private. Operationally, it’s a single entity with unified governance, 20 operational branches, 2,000 employees.
Do CEF and UNICO member pharmacies continue to have cooperative benefits?
Yes. The cooperative model was preserved in the new governance: pharmacist members (over 3,800 at launch, of which 1,200 affiliated to the network) maintain participation rights, discounts, preferential conditions typical of the cooperative model. Losio’s claim “pharmacists for pharmacists” reflects this choice.
Does QFarma have proprietary CeDis like capital pharmacy chains?
The cooperative model is structurally different from the capital chain one. QFarma serves its member pharmacies through the 20 operational branches — functioning as local distribution depots/points — but pharmacies remain independent (pharmacist ownership) and not under chain control. The difference with a chain CeDi (e.g. Hippocrates, Dr.Max) is clear: QFarma is a logistics infrastructure serving its members, not a retail controller.
Will consolidation stop with QFarma?
Hardly. Italian DIF consolidation is a twenty-year structural dynamic (60 wholesalers today vs 120+ in the 1990s) driven by margin pressure, by DD/DPC erosion, by chains and by growing regulatory costs. QFarma is the most visible move of the recent cycle, but it’s plausible to see other operations in the next 24-36 months: further cooperative aggregations, regional acquisitions by large players, eventually exits of operators who don’t find paths out.
Can a regional independent wholesaler still grow in 2026-2027?
Yes, but on well-identified niches and with solid operational disciplines. “Generalist” growth (more traditional pharmacies, more NHS-regulated revenue) is very difficult in a compressing market. Growth on less-regulated niches (veterinary, parapharmacy, specialty), on under-served geographic areas, on customers primarily valuing service (premium delivery, urgency management) is instead accessible and has found examples of concrete success even in 2025-2026.
In summary
Fourteen months after QFarma’s (CEF + UNICO) operativity, Italian pharmaceutical intermediate distribution has visibly restructured. The new cooperative pole — €2.5 billion revenue, 12,000 pharmacies served, 20 branches, 2,000 employees, over 3,800 pharmacist members — has become the first national cooperative group and narrowed the competitive gap with Comifar.
For regional independent distributors, the new arrangement’s pressure is significant: marginal pharmacy portfolio erosion, commercial conditioning by negotiation benchmark, worsening purchase conditions from manufacturers. The strategic response articulates in three paths: yield to a larger pole, federate with other independents, specialise on less-regulated niches.
On the 2027-2028 horizon, the possible aggregation of cooperatives remaining outside the CEF-UNICO pole (So.Farma.Morra, Sofarma, others) could further change competitive geography, leading to the birth of a second Italian cooperative pole.
A side effect we see on Optivo’s DIF clients: competitive pressure has accelerated the adoption of strategic planning tools. Cost-to-serve, scenario simulation, progressive route recomposition, dynamic replanning — tools that until 18 months ago were evaluated as “nice-to-have evolutions” — are now survival tools for regional independents who want to maintain solid commercial arguments toward their territory’s pharmacies.
If you are a regional distributor evaluating how to reposition in the new post-QFarma competitive geography — which strategic exit path to adopt, how to build a defensible service differentiator — talk to our team. Three months of operational data and a conversation with management help frame concrete choices with the greatest return for your specific profile.